The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.

Supporters

Support the authors with ResearchCoin

Tip RSC

Preprint Server

Topics

Biology

Immunology

Medicine

Pathology

Disease

Show all topics

DOI

10.1101/2021.05.14.444076

License

cc-no